A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life.
End of life
HIV cure research
donations
ethics
human biological materials
immunity
pathogens
tissues
virology
Journal
Pathogens & immunity
ISSN: 2469-2964
Titre abrégé: Pathog Immun
Pays: United States
ID NLM: 101683909
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
03
2023
accepted:
09
05
2023
medline:
30
5
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
epublish
Résumé
Initiated in 2017 after extensive community engagement, the Last Gift program enrolls altruistic volunteers willing to donate their cells and tissues at the end of life to allow studies on HIV reservoir dynamics across anatomical sites. As the Last Gift team received tissue requests outside the scope of HIV cure research, we noticed the absence of guiding frameworks to help prioritize the use of altruistically donated human biological materials. In this commentary, we present a proposed framework for prioritizing the use of donated human biological materials within and outside the end-of-life (EOL) HIV cure research context, using the Last Gift study as an example. First, we discuss regulatory and policy considerations, and highlight key ethical values to guide prioritization decisions. Second, we present our prioritization framework and share some of our experiences prioritizing requests for donated human biological materials within and outside EOL HIV cure research.
Identifiants
pubmed: 37252012
doi: 10.20411/pai.v8i1.583
pii: pai.v8i1.583
pmc: PMC10225111
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-16Subventions
Organisme : NIAID NIH HHS
ID : P01 AI169609
Pays : United States
Informations de copyright
Copyright © Pathogens and Immunity 2021.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Camb Q Healthc Ethics. 2014 Oct;23(4):417-30
pubmed: 25032711
AIDS. 2020 Jun 1;34(7):1089-1092
pubmed: 32287073
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
J Virus Erad. 2020 Aug 25;6(4):100008
pubmed: 33294210
AIDS Behav. 2019 Apr;23(4):973-983
pubmed: 30519903
Nat Med. 2005 Nov;11(11):1145-9
pubmed: 16270065
PLoS One. 2020 Nov 18;15(11):e0242420
pubmed: 33206710
AIDS Res Hum Retroviruses. 2019 Nov/Dec;35(11-12):1174-1180
pubmed: 31441322
AIDS Res Hum Retroviruses. 2022 Aug;38(8):670-682
pubmed: 35778845
Nature. 2021 Jul;595(7867):352
pubmed: 34257439
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1033-1046
pubmed: 32449624
Clin Infect Dis. 2022 Oct 12;75(8):1342-1350
pubmed: 35234862
Hastings Cent Rep. 2008 Mar-Apr;38(2):30-42
pubmed: 18457227
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1071-1082
pubmed: 32449625
J Acquir Immune Defic Syndr. 2003 Jun 1;33 Suppl 2:S171-84
pubmed: 12853867
PLoS One. 2018 Jul 23;13(7):e0199670
pubmed: 30036365
N Engl J Med. 2020 Feb 6;382(6):493-496
pubmed: 32023370
Front Immunol. 2019 Mar 12;10:463
pubmed: 30915086
PLoS One. 2021 Jul 16;16(7):e0254148
pubmed: 34270612
AIDS. 2017 Jan 2;31(1):1-4
pubmed: 27755112
J Assoc Nurses AIDS Care. 2019 Jan-Feb;30(1):119-128
pubmed: 30586089
J Clin Ethics. 2010 Fall;21(3):243-63
pubmed: 21089996
BMC Med Ethics. 2018 Oct 20;19(1):83
pubmed: 30342507
Prog Cardiovasc Dis. 2012 Nov-Dec;55(3):282-9
pubmed: 23217432
Curr HIV/AIDS Rep. 2022 Dec;19(6):566-579
pubmed: 36260191
Transplantation. 2015 Nov;99(11):2252-7
pubmed: 26244717
Health Matrix Clevel. 2015;25:109-38
pubmed: 29485842
J Med Ethics. 2023 May;49(5):305-310
pubmed: 35732421
Nurs Clin North Am. 2018 Mar;53(1):123-135
pubmed: 29362056
Am J Transplant. 2012 Sep;12(9):2273-80
pubmed: 22594620
Ann Intern Med. 2018 Sep 4;169(5):349
pubmed: 30178018
JAMA. 2001 Jan 17;285(3):329-33
pubmed: 11176844
BMJ. 2011 Oct 26;343:d6839
pubmed: 22031927
J Clin Invest. 2020 Apr 1;130(4):1699-1712
pubmed: 31910162
PLoS One. 2021 May 7;16(5):e0250882
pubmed: 33961653